

ADVIK LABORATORIES LIMITED							
Regd. Off. : 138, Roz Ka Meo Industrial Area, Sohna, Distt. Mewat Haryana - 122103							
STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTH ENDED DECEMBER 31, 2016							
CIN : L74899HR1994PLC038300							
Sno.	Particulars	Quarter ended 31.12.2016 (Unaudited)	Quarter ended 30.09.2016 (Unaudited)	Quarter ended 31.12.2015 (Unaudited)	Year to date figures for the current period ended 31.12.2016	Year to date figures for the current period ended 31.12.2015	(Rs. in lacs) Previous Year ended 31.03.2016 (Audited)
1	Income from Operations						
	a. Net Sales/ Income from operation (Net of excise duty)	91.73	72.02	(193.61)	193.44	14.10	26.54
	b. Other Operating Income	8.43	10.61	6.42	37.97	37.96	108.93
	Total Income from Operations (net)	100.16	82.63	(187.19)	231.41	52.06	135.47
2	Expenses						
	a. Cost of material consumed	85.93	41.00	20.79	157.09	22.82	42.78
	b. Purchase of Stock in Trade	-	-	(205.47)	-	-	-
	c. Changes in inventories of finished goods, work in progress & stock in trade	(14.81)	23.84	(12.36)	387.20	(11.48)	(1.43)
	d. Employee benefits expense	19.32	17.92	21.25	55.71	61.39	78.08
	e. Depreciation & amortisation expenses	14.77	14.79	15.76	44.28	46.93	62.49
	(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	19.88	15.34	16.59	49.25	44.49	65.35
	Total Expenses	125.09	112.89	(143.44)	693.53	164.15	247.27
3	Profit/(Loss) from operations before other income, Finance Costs and Exceptional Items(1-2)	(24.93)	(30.26)	(43.75)	(462.12)	(112.09)	(111.80)
4	Other Income	1.63	-	0.15	2.43	0.19	0.35
5	Profit/(Loss) from ordinary activities before finance costs & exceptional items(3+4)	(23.30)	(30.26)	(43.60)	(459.69)	(111.90)	(111.45)
6	Finance Costs	0.04	0.02	0.06	0.09	27.25	8.22
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items(5-6)	(23.34)	(30.28)	(43.66)	(459.78)	(139.15)	(119.67)
8	Exceptional Items	-	-	-	-	-	-
9	Profit/(loss) from Ordinary Activities before tax (7+8)	(23.34)	(30.28)	(43.66)	(459.78)	(139.15)	(119.67)
10	Tax Expense	-	-	-	-	-	(0.66)
11	Net Profit/Loss from Ordinary Activities after Tax (9-10)	(23.34)	(30.28)	(43.66)	(459.78)	(139.15)	(119.01)
12	Extra ordinary Items (net of tax)				-	-	-
13	Net Profit / (Loss) after taxes but before share of profit / (loss) of associates and minority interest (11+12)	(23.34)	(30.28)	(43.66)	(459.78)	(139.15)	(119.01)
14	Share of Profit/(Loss) of Associates	-	-	-	-	-	-
15	Minority Interest	-	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15)	(23.34)	(30.28)	(43.66)	(459.78)	(139.15)	(119.01)
17	Paid up Equity Share Capital (Rs. 10/- per share)	1,911.14	1,911.14	1,911.14	1,911.14	1,911.14	1,911.14
18	Reserve excluding revaluation reserves as per balance sheet of previous accounting year			-	-	-	(12.85)
19	Earning per share (before extra ordinary items) of Rs. 10/- per share. (not annualised)						
	a) Basic	(0.12)	(0.16)	(0.23)	(2.41)	(0.73)	(0.62)
	b) Diluted	(0.12)	(0.16)	(0.23)	(2.41)	(0.73)	(0.62)
20	Earning per share (after extra ordinary items) of Rs. 10/- per share. (not annualised)						
	a) Basic	(0.12)	(0.16)	(0.23)	(2.41)	(0.73)	(0.62)
	b) Diluted	(0.12)	(0.16)	(0.23)	(2.41)	(0.73)	(0.62)

Notes :

- The above financial results have been reviewed by the Audit Committee & approve by the Board of Directors in the meeting held on February 14, 2017.
- The Statutory Auditors have carried out the "Limited Review" of the Standalone financial results of the Company for the quarter & nine months ended December 31, 2016 in accordance with regulation 33 of the SEBI (LODR) Regulations, 2015.
- The statement of unaudited financial results for the quarter and nine month ended 31st December, 2016 has been prepared following the same accounting policies as were followed in the annual financial statement for the year ended 31st March, 2016.
- The Company is engaged in pharmaceuticals business only & therefore, there is only one reportable segment as per AS-17 issued by the ICAI.
- No investor complaint was pending as on 31st December, 2016 and no complaint was received during the quarter under review.
- Previous year/period figures have been regrouped/rearranged, wherever necessary to make them comparable with the current period figure.

Place: New Delhi

Date : 14th February, 2017

For and on behalf of Board of Directors of
Advik Laboratories Limited

(Peeyush Kumar Aggarwal)

Chairman

DIN : 00090423

